Pharmaron Beijing (SHE:300759) forecasts a 4% to 10% rise in its net attributable profit to between 729.5 million yuan and 771.5 million yuan in the first half from 701.4 million yuan in the year-ago period, according to a Tuesday filing with the Shenzhen bourse.
The drug research company expects earnings per share to grow to between 0.4024 yuan and 0.4256 yuan from 0.3984 yuan in the year-ago period.
Revenue is expected to rise 16% to 19% to between 7.47 billion yuan and 7.66 billion yuan from 6.44 billion yuan in the prior-year period.
Pharmaron attributed the expected rise to an increase in new orders following the advancement of its small molecule CDMO service pipeline.